Drugs / Sodium Iodide I 131
last change Jul 2024 re-read 2 minutes ago

Sodium Iodide I 131

Developed for
thyroid cancer
Investigated by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Peking Union Medical College Hospital

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) HICON 2005-05-19 fda.gov
Approved US (FDA) IODOTOPE 1957-05-02 fda.gov

Trials 1 · a red edge is where a trial was stopped

today
US approved 1957
NCT04952493 · Ph 2
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04952493 Sep 2021 → Jul 2023 thyroid cancer Peking Union Medical College Hospital Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Sodium Iodide I 131 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04952493